Damora Therapeutics, Inc. (NASDAQ: DMRA) is a Healthcare company (Biotechnology) with a market capitalization of $1.4B. The Maz Rating grades it against the other companies in its sector.
Damora Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $22.22, Damora Therapeutics, Inc. trades at 2.8x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -66.2%, return on invested capital of -61.3% and a free cash flow yield of -4.3%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 14.80. Over the past 52 weeks the share price ranged from $15.76 to $38.33, with a beta of 1.51.
Damora Therapeutics, Inc. does not currently pay a dividend.
3 Wall Street analyst ratings cover the stock: 3 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Damora Therapeutics, Inc. (DMRA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 38.2% / 30% · Interest income / Revenue 415900000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 38.2% / 33% · Receivables / Mkt Cap (36m) 0.06% / 49% · Interest income / Revenue 415900000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 38.2% / 33.33% · Receivables / Mkt Cap (24m) 0.06% / 33.33% · Interest income / Revenue 415900000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.07% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 99.3% / 33.33% · Receivables / Avg Assets (4Q) 0.19% / 33.33% · Interest income / Revenue 415900000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 99.2% / 33.33% · (Cash+Recv) / Total Assets 99.4% / 33.33% · Interest income / Revenue 415900000.0% / 5% | Fail |
No. As of September 2026, Damora Therapeutics, Inc. (DMRA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Damora Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 415900000.0% of each dividend: Damora Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.